ESARTAN AP TAB - Dr Precision is an advanced fixed-dose triple combination tablet comprising Telmisartan 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg, specifically formulated for patients with moderate to severe hypertension who require comprehensive multi-drug therapy. Manufactured by BluepillExpress under the Dr Precision label, this once-daily oral tablet brings together three distinct pharmacological actions to deliver superior blood pressure regulation and organ protection. Telmisartan, a potent angiotensin II receptor blocker (ARB), provides long-lasting inhibition of vasoconstriction and aldosterone-mediated sodium retention, supporting sustained 24-hour blood pressure control. Amlodipine, a calcium channel blocker, facilitates peripheral vasodilation by blocking calcium influx into vascular smooth muscle cells, reducing systemic vascular resistance. Hydrochlorothiazide, a thiazide diuretic, enhances sodium and water excretion, lowering plasma volume and further decreasing vascular resistance. This synergistic triple mechanism ensures optimal management of Stage II or resistant hypertension, especially in high-risk cardiovascular and diabetic patients, improving arterial compliance, stroke volume, and renal outcomes. Ideal for global pharmaceutical distribution through private labelling, institutional tenders, and chronic disease portfolios, ESARTAN AP TAB meets GMP quality standards and is tailored to address the complexities of hypertension unresponsive to dual therapies and post-stroke/post-MI management.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Telmisartan 40 mg, Amlodipine 5 mg, Hydrochlorothiazide 12.5 mg |
| Dosage Form | Oral tablet, once daily |
| Therapeutic Indications | Moderate to severe hypertension, resistant hypertension, high-risk cardiovascular hypertensives, diabetic hypertensives with renal risk, post-stroke/post-MI management |
| Mechanism of Action | Combination of ARB (Telmisartan), Calcium channel blocker (Amlodipine), and Thiazide diuretic (Hydrochlorothiazide) for multi-pathway blood pressure control |
| Pharmacological Benefits | Sustained 24-hour blood pressure control, reduced vascular resistance, decreased plasma volume, improved arterial compliance and renal protection |
| Manufacturing Standards | GMP-compliant, Dr Precision label, BluepillExpress manufacturer |
| Target Market | Global pharmaceutical markets including private labelling, institutional tenders, and chronic disease portfolios |
| Blood Pressure Control Efficacy | Effective in Stage II and resistant hypertension where dual therapies are insufficient |
| Attributes | Description |
|---|---|
| Telmisartan Dose | 40 mg |
| Amlodipine Dose | 5 mg |
| Hydrochlorothiazide Dose | 12.5 mg |
| Tablet Type | Fixed-dose combination |
| Administration Route | Oral |
| Frequency | Once daily |
| Packaging | Available for private labelling and institutional distribution |
| Manufacturing Compliance | GMP certified |
| Label | Dr Precision |
| Manufacturer | BluepillExpress |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
ESARTAN AP TAB combines Telmisartan, Amlodipine, and Hydrochlorothiazide in a fixed-dose formulation to target three distinct mechanisms of blood pressure control, providing enhanced efficacy in patients whose hypertension is resistant to dual drug regimens.
The Telmisartan component reduces aldosterone activity, lowering renal sodium retention, while Amlodipine improves arterial compliance and Hydrochlorothiazide reduces plasma volume, collectively protecting renal function in diabetic hypertensive patients.
Yes, the comprehensive blood pressure control offered by the triple combination in ESARTAN AP TAB makes it effective for managing hypertension in post-stroke and post-MI patients to reduce cardiovascular risks.
ESARTAN AP TAB is manufactured under GMP-compliant conditions by BluepillExpress and marketed under the Dr Precision brand, ensuring high-quality, precision formulation standards.
Yes, ESARTAN AP TAB is designed to cater to global pharmaceutical markets, including availability for private labelling and institutional procurement, making it suitable for chronic disease product portfolios.
Country Of Origin: India
ESARTAN AP TAB is a fixed-dose triple combination of Telmisartan 40 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg, designed for patients with moderate to severe hypertension who require multi-drug therapy. Manufactured and exported by BluepillExpress, this once-daily oral tablet offers synergistic blood pressure control via three mechanisms: renin-angiotensin inhibition, calcium channel blockade, and diuresis. It is ideal for global pharmaceutical markets through private labelling, institutional tenders, and chronic disease product portfolios.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
ESARTAN AP TAB, proudly manufactured by BluepillExpress, is a powerful triple combination antihypertensive therapy engineered for patients who fail to achieve optimal blood pressure control on dual drug regimens. This once-daily oral tablet combines three well-established antihypertensive agents—Telmisartan, Amlodipine, and Hydrochlorothiazide—each targeting a unique physiological pathway to ensure comprehensive blood pressure reduction and end-organ protection.
Telmisartan is a potent ARB (angiotensin II receptor blocker) that prevents vasoconstriction and aldosterone-mediated sodium retention by blocking angiotensin II at its receptor site. It offers a long half-life, enabling sustained 24-hour blood pressure control.
Amlodipine, a dihydropyridine calcium channel blocker, induces peripheral vasodilation by inhibiting calcium influx into smooth muscle cells, thereby lowering systemic vascular resistance.
Hydrochlorothiazide (HCTZ) is a thiazide diuretic that reduces blood volume and vascular resistance by enhancing sodium and water excretion from the distal convoluted tubules.
Together, these three agents provide synergistic control over systolic and diastolic pressure, and significantly improve arterial compliance, stroke volume, and renal outcomes, especially in high-risk populations.
✅ Therapeutic Indications
Stage II or Resistant Hypertension
High-risk cardiovascular hypertensive patients
Diabetic hypertensives with renal risk
Hypertension unresponsive to dual therapy
Post-stroke or post-MI hypertensive management
✅ Mechanism of Action
Telmisartan: Inhibits AT1 receptors → vasodilation and reduced aldosterone levels
Amlodipine: Blocks calcium entry → smooth muscle relaxation and reduced resistance
HCTZ: Inhibits Na+/Cl− co-transporter → decreased plasma volume and BP
This triple-action ensures maximum antihypertensive efficacy while minimizing side effects through lower individual doses.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
